文献速递临床试验与 GCP真实世界研究与卫生经济

马尿酸乌洛托品预防女性复发性尿路感染的非劣效性试验:ALTAR研究方案

ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial.
PubMed 文献 · Trials · 2018-11-09

ALTAR是一项多中心、实用性、患者随机、非劣效性试验,比较非抗生素预防药物马尿酸乌洛托品与每日低剂量抗生素预防女性复发性尿路感染(rUTI)的效果。研究对象为需要预防治疗的rUTI女性,主要结局是12个月预防治疗期间患者自报的症状性需抗生素治疗的UTI发生率,并评估卫生经济学结局。

要点

  • 比较马尿酸乌洛托品与低剂量抗生素预防女性rUTI的非劣效性。
  • 主要结局为12个月治疗期内自报的症状性抗生素治疗UTI发生率。
  • 纳入标准包括1年内3次或6个月内2次rUTI,或单次严重感染需住院。

核心结论

  • 该研究旨在评估马尿酸乌洛托品预防女性rUTI是否非劣效于每日低剂量抗生素。

研究设计与样本

  • 多中心、实用性、患者随机、非劣效性试验,计划从英国二级保健泌尿科/泌尿妇科招募rUTI女性。
  • 参与者接受12个月预防治疗,并在治疗完成后随访6个月。

关键数值与推荐

  • rUTI定义:1年内3次发作或6个月内2次发作,或单次严重感染需住院。
  • 主要结局:12个月预防治疗期间参与者自报的症状性抗生素治疗UTI发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At least half of all adult women will experience infective cystitis (urinary tract infection: UTI) at least once in their life and many suffer from repeated episodes. Recurrent urinary tract infection (rUTI) in adult women is usually treated with long-term, low-dose antibiotics and current national and international guidelines recommend this as the 'gold standard' preventative treatment. Although they are reasonably effective, long-term antibiotics can result in bacteria becoming resistant not only to the prescribed antibiotic but to other antimicrobial agents. The problem of antimicrobial resistance is recognised as a global threat and the recent drive for antibiotic stewardship has emphasised the need for careful consideration prior to prescribing antibiotics. This has led clinicians and patients alike to explore potential non-antibiotic options for recurrent UTI prevention. DESIGN /METHODS: This is a multicentre, pragmatic, patient-randomised, non-inferiority trial comparing a non-antibiotic preventative treatment for rUTI in women, methenamine hippurate, against the current standard of daily low-dose antibiotics. Women who require preventative treatment for rUTI are the target population. This group is comprised of those with a diagnosis of rUTI, defined as three episodes in 1 year or two episodes in 6 months, and those with a single severe infection requiring hospitalisation. Participants will be recruited from secondary care urology / urogynaecology departments in the UK following referral with rUTI. Participants will be followed up during a 12-month period of treatment and in the subsequent 6 months following completion of the prophylactic medication. Outcomes will be assessed from patient recorded symptoms, quality of life questionnaires and microbiological examination of urine and perineal swabs. The primary outcome is the incidence of symptomatic antibiotic-treated UTI self-reported by participants during the 12-month period of preventative treatment. Health economic outcomes will also be assessed to define the cost-effectiveness of both treatments. A qualitative study will be conducted in the first 8 months of the trial to explore with participants/non-participants' and recruiting clinicians' views on trial processes and identify potential barriers to recruitment, reasons for participating and non-participation and for dropping out of the study. DISCUSSION: The study was commissioned and funded by the National Institute for Health Research (NIHR) and approved under the Medicines and Healthcare products Regulatory Agency (MHRA) notification scheme as a 'Type A' study. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number (ISRCTN), registry number: ISRCTN70219762 . Registered on 31 May 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Forbes R, Ali A, Abouhajar A, et al. ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial. Trials. 2018. PMID: 30413181. doi:10.1186/s13063-018-2998-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。